rhIGF-I/rhIGFBP-3

DRUG3 trials

Sponsors

Insmed Incorporated, Shire

Conditions

Growth Hormone Insensitivity Syndrome (GHIS)Laron SyndromeMyotonic Dystrophy Type 1Retinopathy of Prematurity (ROP)

Phase 2

IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome

CompletedNCT00368173

Insmed IncorporatedGrowth Hormone Insensitivity Syndrome (GHIS), Laron Syndrome

Updated: 2012-09-13

Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1

CompletedNCT00577577

Insmed IncorporatedMyotonic Dystrophy Type 1

Start: 2007-12-31End: 2008-12-29Updated: 2022-01-06

IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity

CompletedNCT01096784

ShireRetinopathy of Prematurity (ROP)

Start: 2010-06-18End: 2016-03-30Updated: 2021-06-14

Related Papers

Randomized Control Trial of Postnatal rhIGF-1/rhIGFBP-3 Replacement in Preterm Infants: Post-hoc Analysis of Its Effect on Brain Injury

Frontiers in Pediatrics2020-10-0912 citations

Elevated levels of IL-6 and IGFBP-1 predict low serum IGF-1 levels during continuous infusion of rhIGF-1/rhIGFBP-3 in extremely preterm infants.

2019-11-0911 citations

rhIGF-1/rhIGFBP-3 in Preterm Infants: A Phase 2 Randomized Controlled Trial.

2018-11-22113 citations

Continuous longitudinal infusion of rhIGF-1/rhIGFBP-3 in extremely preterm infants: Evaluation of feasibility in a phase II study

Growth Hormone & IGF Research2017-08-3127 citations